Research Topics

Ajay K Kakkar

Summary

Affiliation: Thrombosis Research Institute
Country: UK

Publications

  1. Kakkar A, Brenner B, Dahl O, Eriksson B, Mouret P, Muntz J, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372:31-9 pubmed publisher
    ....
  2. request reprint
    Kakkar A, Levine M, Kadziola Z, Lemoine N, Low V, Patel H, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004;22:1944-8 pubmed
    ..However, the observed improved survival in a subgroup of patients with a better prognosis suggests a potential modifying effect of dalteparin on tumor biology. ..
  3. Kakkar A, Macbeth F. Antithrombotic therapy and survival in patients with malignant disease. Br J Cancer. 2010;102 Suppl 1:S24-9 pubmed publisher
    ..This paper includes a summary of the data presented at the meeting and explores potential mechanisms by which antithrombotic agents might exert antitumour effects. The summary is followed by a consensus statement developed by the group. ..
  4. Kakkar A, Mueller I, Bassand J, Fitzmaurice D, Goldhaber S, Goto S, et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2012;163:13-19.e1 pubmed publisher
    ....
  5. Kakkar A, Cimminiello C, Goldhaber S, Parakh R, Wang C, Bergmann J. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med. 2011;365:2463-72 pubmed publisher
    ..Funded by Sanofi; LIFENOX ClinicalTrials.gov number, NCT00622648.). ..

Locale

Collaborators

Detail Information

Publications5

  1. Kakkar A, Brenner B, Dahl O, Eriksson B, Mouret P, Muntz J, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372:31-9 pubmed publisher
    ....
  2. request reprint
    Kakkar A, Levine M, Kadziola Z, Lemoine N, Low V, Patel H, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004;22:1944-8 pubmed
    ..However, the observed improved survival in a subgroup of patients with a better prognosis suggests a potential modifying effect of dalteparin on tumor biology. ..
  3. Kakkar A, Macbeth F. Antithrombotic therapy and survival in patients with malignant disease. Br J Cancer. 2010;102 Suppl 1:S24-9 pubmed publisher
    ..This paper includes a summary of the data presented at the meeting and explores potential mechanisms by which antithrombotic agents might exert antitumour effects. The summary is followed by a consensus statement developed by the group. ..
  4. Kakkar A, Mueller I, Bassand J, Fitzmaurice D, Goldhaber S, Goto S, et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2012;163:13-19.e1 pubmed publisher
    ....
  5. Kakkar A, Cimminiello C, Goldhaber S, Parakh R, Wang C, Bergmann J. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med. 2011;365:2463-72 pubmed publisher
    ..Funded by Sanofi; LIFENOX ClinicalTrials.gov number, NCT00622648.). ..